Home » Topics » Regulatory » EMA

EMA
RSS

FDA issues public health advisory for Raptiva, EMEA recommends suspension

Feb. 23, 2009

CHMP recommends granting marketing authorization to Nycomed's Pantozol Control

Feb. 20, 2009

Merck Sharp & Dohme withdraws MAA to EMEA for vorinostat MSD in CTCL

Feb. 19, 2009

CHMP recommends new indication for Nycomed's TachoSil

Dec. 29, 2008

CHMP recommends marketing authorization for Pfizer's Fablyn in osteoporosis

Dec. 29, 2008

Oncoscience withdraws Theraloc (nimotuzumab) marketing authorization application

Dec. 5, 2008

Further explanation of CHMP's negative opinion for Santhera's Sovrima for Friedreich's ataxia

Nov. 25, 2008

EMEA recommends temporary suspension of Acomplia marketing authorization in obese patients

Oct. 24, 2008

EMEA withdraws marketing authorization for Protopy in the European Union

Oct. 9, 2008

CHMP recommends variations to marketing authorization of Cancidas

Sep. 30, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.